HUMMELSTOWN, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based…
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30,…
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for…
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused…
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in…
Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK /…
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company…